The role of placebo and nocebo effects-that is positive or negative treatment effects that are entirely a consequence of the patient's expectations and beliefs about a treatment outcome in terms of efficacy, safety, usability or side effects-has been shown for almost all types of diseases and physiological response systems. Evidence for the relevance of placebo and nocebo effects in dermatology is also increasing, particularly for symptoms of itch and learned (conditioned) immune function. In addition, increasing knowledge is available about the neurobiological mechanisms of action, such as the role of the dopaminergic system. Studies on this topic offer innovative perspectives to unravel the multifactorial pathways of treatment effects and to use research designs for experimental research that provide full insight into the role of placebo and nocebo effects. Moreover, intervention strategies can be developed for dermatology practice that optimize regular treatments with innovative non-pharmacological treatment strategies (e.g. optimized doctor-patient communication and treatment adherence, or prevention of nocebo reactions with regard to adverse side effects). In addition, evidence on learned immune function offers new pathways to optimize pharmacological treatments (e.g. dosage adjustments and conditioning of physiological responses), the ultimate goal being to prevent individual treatment failures and maximize regular treatment effects.
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EvErs with both humans and animals starting to scratch themselves after viewing others scratching (s16-s18). Direct evidence for placebo and nocebo induction on itch has been delivered by experimental studies that support the role of both conscious and automatic learning processes, such as verbal suggestions and conditioning (s19-s22). [3] [4] [5] In one of the first experiments, negative suggestions about a histamine application resulted in higher itch scores (s19). In a study comparing itch and pain symptoms, nocebo effects were induced for both itch and pain after the verbal suggestion that the majority of subjects generally experienced high levels of itch or pain in response to the stimuli applied. 3 In line with research in other areas, such as pain, placebo and nocebo effects on itch can be induced most effectively by combining automatic and conscious processes, specifically conditioning and verbal suggestions (s20-s22). 4, 5 These effects also play a role in dermatological research and practice, as is shown by a meta-analysis of clinical trials of oral systemic medication for psoriasis, atopic dermatitis and urticaria, showing moderate to large effects on itch of placebo medication (without any treatment ingredients). 6 These experimental
and clinical studies clearly demonstrate the significance of placebo and nocebo effects in itch treatments and offers possible explanations for itch sensitization in patients suffering from chronic itch (s23). Preliminary evidence for the possible neurobiological pathways comes from a study examining nocebo effects in itch in patients with atopic dermatitis, 4 showing that when applying saline while patients expected a real allergen, similar brain responses were observed as with the previously applied real allergen, with greater activation in the striatum and the dorsolateral prefrontal cortex. These regions have previously also been linked to placebo-or nocebo-induced brain processes related to pain and its regulation (s24-s25).
Placebo and nocebo effects have also been shown to impact physiological pathways. Animal and human studies have shown that physiological reactions of histamine release, for example, can be the result of learning processes such as conditioning (s6-s10). 1 In conditioning trials, a pharmacological agent such as cyclosporine is combined with a neutral cue such as a specific beverage. When later exposed only to the beverage, as a conditioned stimulus, participants show comparable immune reactions as previously to the drug. Specific endocrine reactions, such as insulin reactions, have also been shown to be susceptible to conditioning (s10-s11). Particularly relevant for dermatology are the animal and human studies of conditioning anti-allergic reactions (s7, s9). 7, 8 In the first study in humans, patients with allergies were given an antihistamine in combination with a distinct beverage for several days. When the patients were later exposed only to the beverage, they had less severe subjective symptoms and a reduced skin 
| HOW PLACEBO AND NOCEBO EFFECTS WORK AND AFFECT BODILY FUNCTIONS
Research has evolved our understanding about the specific psychoneurobiological mechanisms through which placebo and nocebo effects work. Placebo effects influence treatments through mechanisms of expectancies; these include conscious learning processes, such as verbal suggestions and instructions by a doctor, and more automatic learning processes of conditioning (s2, s15). 1,2 The most effective strategy for reducing acute symptoms during a medical procedure appears to be verbal suggestions, for example by a medical doctor before surgery (s26). To obtain more stable placebo and nocebo effects, the combination of both conscious and automatic processes is most effective, as has been shown for a broad variety of symptoms and conditions, including itch (s2, s15). 1,2 For these longerterm placebo or nocebo effects, conditioning is a necessary learning mechanism, particularly when focusing on changes in the physiological response systems, such as immune and endocrine functioning (s6-s10). Conditioning as a learning mechanism can also explain the large role of individual and environmental influences-such as personality characteristics of patients and doctors' white coats or technical instruments-on the effectiveness of the placebo or nocebo effect for a specific treatment (s3-s5). 1, 2 There is, for example, preliminary evidence that placebo effects vary with regard to the type of treatment (e.g.
larger effects for intra-articular, subcutaneous and topical treatments than for oral treatments, and stimulant effects for red oral drugs (s27-s29), age groups (e.g. possibly stronger effects in children) (s30-s31), individual differences between patients (e.g. stronger placebo effects for more optimistic individuals and stronger nocebo effects for individuals with more worrying and negative attitudes towards medication) 5 (s5, s24, s32) and cultural differences (e.g. particular large placebo analgesic effects in US trials, possibly due to cultural differences in communication styles about expected drug effects) (s33). 
| WHAT ARE THE IMPLICATIONS OF PLACEBO AND NOCEBO EFFECTS FOR DERMATOLOGICAL PRACTICE?
Particularly the neurobiological insights into how placebo and nocebo effects affect bodily functions contributed to the renewed research attention in this area. This may also have important implications for dermatological research and practice.
1.
Dermatologists and their patients need to be aware that treatment outcomes in terms of efficacy and side effects can be partly attributed to their expectations about the treatments.
Although there are no precise effect sizes of placebo and nocebo effects in the area of dermatology yet, results suggest that effects on itch are at least similar as or even stronger than on pain. 3, 6 This is possibly due to the high suggestibility of itch. Also, animal and human studies have yielded convincing evidence that learned (conditioned) immune functioning is possible (e.g. conditioning of antihistamines or cyclosporine) (s6-s10). 
Insurance companies, the pharmaceutical industry and research
foundations should realize that placebo responses can be used to optimize treatment outcomes in terms of increased effectiveness, fewer side effects and lower costs.
In view of the evidence for learned immune functioning based on conditioning principles, questions arise as to why these potential effects are not more systematically used to optimize our treatments.
All pharmacological therapies make use of placebo effects, if perhaps unintentionally, when a patient starts a new treatment: they promise a better outcome. At the same time, the large heterogeneity in the long-term efficacy of many treatments might be at least partly a consequence of a lack of enduring placebo effects, as the conditioning effects are likely to be extinguished when subjects are not systematically reexposed to the drug on the basis of conditioning principles (s41). The results of clinical studies (e.g. for pharmacological treatments in ADHD and hormonal ointments in psoriasis) that showed comparable treatment effects or fewer side effects when the dosage of regular treatment was reduced after a period of conditioning 9 (s38-s39) support the idea that the dosage of medication can be adjusted when making full use of possible conditioning effects. This also implies considerable possibilities for developing new treatments. Every drug or medication can be tested on its ability to enhance its effects by means of conditioning, to produce the same physiological reactions without the drug.
This knowledge provides important opportunities for new treatment developments in terms of higher efficacy, fewer side effects and lower treatment costs. This has considerable relevance for research foundations, the pharmacological industry and insurance companies. The next challenging step will be to translate this knowledge into regular treatment options that make optimal use of a combination of regular drug therapy with conditioning principles of our physiological response systems, with the ultimate goal of preventing individual treatment failures and maximizing our treatments for all patients.
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